A176750 Stock Overview
Engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
DuChemBIO Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩14,300.00 |
52 Week High | ₩19,570.00 |
52 Week Low | ₩5,050.00 |
Beta | 0 |
11 Month Change | -17.86% |
3 Month Change | 11.63% |
1 Year Change | 160.00% |
33 Year Change | 76.54% |
5 Year Change | 44.01% |
Change since IPO | 35.55% |
Recent News & Updates
Recent updates
Shareholder Returns
A176750 | KR Medical Equipment | KR Market | |
---|---|---|---|
7D | -8.7% | -3.0% | -1.8% |
1Y | 160.0% | 8.3% | -4.3% |
Return vs Industry: A176750 exceeded the KR Medical Equipment industry which returned 8.3% over the past year.
Return vs Market: A176750 exceeded the KR Market which returned -4.3% over the past year.
Price Volatility
A176750 volatility | |
---|---|
A176750 Average Weekly Movement | 7.4% |
Medical Equipment Industry Average Movement | 7.0% |
Market Average Movement | 5.7% |
10% most volatile stocks in KR Market | 11.8% |
10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A176750 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A176750's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | n/a | n/a | www.duchembio.com |
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease.
DuChemBIO Co.,Ltd. Fundamentals Summary
A176750 fundamental statistics | |
---|---|
Market cap | ₩385.91b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A176750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A176750 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A176750 perform over the long term?
See historical performance and comparison